Molecular cytogenetic identification of subgroups of grade III invasive ductal breast carcinomas with different clinical outcomes

Clinical Cancer Research

Volumn 10, Issue 18 I, 2004, Pages 5988-5997

  Jones, Chris ^a   Ford, Emily ^a   Gillett, Cheryl ^b   Ryder, Ken ^b   Merrett, Samantha ^a   Reis Filho, Jorge S ^a   Fulford, Laura G ^a,c   Hanby, Andrew ^d   Lakhani, Sunil R ^a,e  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b GUY S HOSPITAL   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^e ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKERATIN 14; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ARTICLE; BREAST CARCINOMA; CANCER GRADING; CANCER INVASION; CHROMOSOME 13Q; CHROMOSOME 16P; CHROMOSOME 17P; CHROMOSOME 17Q; CHROMOSOME 19P; CHROMOSOME 19Q; CHROMOSOME 20P; CHROMOSOME 20Q; CHROMOSOME 4Q; CHROMOSOME 7Q; CHROMOSOME 8Q; CHROMOSOME 9P; CHROMOSOME XP; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ALGORITHMS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CHROMOSOME ABERRATIONS; CYTOGENETICS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KERATINS; LYMPHATIC METASTASIS; MULTIVARIATE ANALYSIS; NUCLEIC ACID HYBRIDIZATION; PHENOTYPE; PROGNOSIS; RECEPTORS, PROGESTERONE; TIME FACTORS;

EID: 4644231521     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-03-0731     Document Type: Article

References (34)

1. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. "Histopathology 1991;19:403-10.
2. Gusterson BA, Warburton MJ, Mitchell D, Ellison M, Neville AM, Rudland PS. Distribution of myoepithelial cells and basement membrane proteins in the normal breast and in benign and malignant breast diseases Cancer Res 1982;42:4763-70.
3. Dairkee SH, Blayney C, Smith HS, Hackett AJ. Monoclonal antibody that defines human myoepithelium Proc Natl Acad Sci USA 1985;82:7409-13.
4. Altmannsberger M, Dirk T, Droese M, Weber K, Osborn M. Keratin polypeptide distribution in benign and malignant breast tumors: subdivision of ductal carcinomas using monoclonal antibodies. "Virchows Arch B Cell Pathol Incl Mol Pathol 1986;51:265-75.
5. Nagle RB, Bocker W, Davis JR, Heid HW, Kaufmann M, Lucas DO, Jarasch ED. Characterization of breast carcinomas by two monoclonal antibodies distinguishing myoepithelial from luminal epithelial cells J Histochem Cytochem 1986;34:869-81.
6. Dairkee SH, Ljung BM, Smith H, Hackett A. Immunolocalization of a human basal epithelium specific keratin in benign and malignant breast disease Breast Cancer Res Treat 1987;10:11-20.
7. Jarasch ED, Nagle RB, Kaufmann M, Maurer C, Bocker WJ. Differential diagnosis of benign epithelial proliferations and carcinomas of the breast using antibodies to cytokeratins Hum Pathol 1988;19:276-89.
8. Wetzels RH, Holland R, van Haelst UJ, Lane EB, Leigh IM, Ramaekers FC. Detection of basement membrane components and basal cell keratin 14 in noninvasive and invasive carcinomas of the breast Am J Pathol 1989;134:571-9.
9. Gould VE, Koukoulis GK, Jansson DS, Nagle RB, Franke WW, Moll R. Coexpression patterns of vimentin and glial filament protein with cytokeratins in the normal, hyperplastic, and neoplastic breast Am J Pathol 1990;137:1143-55.
10. Wetzels RH, Kuijpers HJ, Lane EB, et al. C. Basal cell-specific and hyperproliteration-related keratins in human breast cancer Am J Pathol 1991;138:751-63.
11. Heatley M, Maxwell P, Whiteside C, Toner P. Cytokeratin intermediate filament expression in benign and malignant breast disease J Clin Pathol 1995;48:26-32.
12. Santini D, Ceccarelli C, Taffurelli M, Pileri S, Marrano D. Differentiation pathways in primary invasive breast carcinoma as suggested by intermediate filament and biopathological marker expression J Pathol 1996;179:386-91.
13. Rejthar A, Nenutil R. The intermediate filaments and prognostically oriented morphological classification in ductal breast carcinoma. Neoplasma 1997;44:370-3.
14. Malzahn K, Mitze M, Thoenes M, Moll R. Biological and prognostic significance of stratified epithelial cytokeratins in infiltrating ductal breast carcinomas Virchows Arch 1998;433:119-29.
15. Tsuda H, Takarabe T, Hasegawa T, Murata T, Hirohashi S. Myoepithelial differentiation in high-grade invasive ductal carcinomas with large central acellular zones Hum Pathol 1999;30:1134-9.
16. Jones C, Nonni AV, Fulford L, et al. CGH analysis of ductal carcinoma of the breast with basaloid/myoepithelial cell differentiation Br J Cancer 2001;85:422-7.
17. van de Rijn M, Perou CM, Tibshirani R, et al. Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome Am J Pathol 2002;161:1991-6.
18. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours Nature 2000;406:747-52.
19. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications Proc Natl Acad Sci USA 2001;98:10869-74.
20. Lakhani SR, Van De Vijver MJ, Jacquemier J, et al. The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol 2002;20:2310-8.
21. Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003;10:8418-23.
22. Tsuda H, Takarabe T, Hasegawa F, Fukutomi T, Hirohashi S. Large, central acellular zones indicating myoepithelial tumor differentiation in high-grade invasive ductal carcinomas as markers of predisposition to lung and brain metastases. Am J Surg Pathol 2000;24:197-202.
23. Gillett CE, Miles DW, Ryder K, et al. Retention of the expression of E-cadherin and catenins is associated with shorter survival in grade III ductal carcinoma of the breast J Pathol 2001;193:433-41.
24. Barnes DM, Harris WH, Smith P, Millis RR, Rubens RD. Immunohistochemical determination of oestrogen receptor: comparison of different methods of assessment of staining and correlation with clinical outcome of breast cancer patients Br J Cancer 1996;74:1445-51.
25. Jones C, Damiani S, Wells D, Chaggar R, Lakhani SR, Eusebi V. Molecular cytogenetic comparison of apocrine hyperplasia and apocrine carcinoma of the breast Am J Pathol 2001;158:207-14.
26. Wells D, Sherlock JK, Handyside AH, Delhanty JD. Detailed chromosomal and molecular genetic analysis of single cells by whole genome amplification and comparative genomic hybridisation Nucleic Acids Res 1999;27:1214-8.
27. Tibshirani R, Hastie T, Narasimhan B, Chu G. Diagnosis of multiple cancer types by shrunken centroids of gene expression Proc Natl Acad Sci USA 2002;99:6567-72.
28. Buerger H, Otterbach F, Simon R, et al. Different genetic pathways in the evolution of invasive breast cancer are associated with distinct morphological subtypes J Pathol 1999;189:521-6.
29. Roylance R, Gorman P, Harris W, et al. Comparative genomic hybridization of breast tumors stratified by histological grade reveals new insights into the biological progression of breast cancer Cancer Res 1999;59:1433-6.
30. Buerger H, Mommers EC, Littmann R, et al. Ductal invasive G2 and G3 carcinomas of the breast are the end stages of at least two different lines of genetic evolution J Pathol 2001;194:165-70.
31. Roylance R, Gorman P, Hanby A, Tomlinson I. Allelic imbalance analysis of chromosome 16q shows that grade I and grade III invasive ductal breast cancers follow different genetic pathways J Pathol 2002;196:32-6.
32. Jimenez RE, Wallis T, Visscher DW. Centrally necrotizing carcinomas of the breast: a distinct histologic subtype with aggressive clinical behavior Am J Surg Pathol 2001;25:331-7.
33. Korsching E, Packeisen J, Agelopoulos K, et al. Cytogenetic alterations and cytokeratin expression patterns in breast cancer: integrating a new model of breast differentiation into cytogenetic pathways of breast carcinogenesis. Lab Invest 2002;82:1525-33.
34. Jones C, Foschini MP, Chaggar R, et al. Comparative genomic hybridization analysis of myoepithelial carcinoma of the breast. Lab Invest 80:831-6, 2000.